AUTHOR=Shi Nan-Rui , Wang Qi , Liu Jie , Zhang Ji-Zhou , Deng Bin-Lu , Hu Xiu-Min , Yang Jie , Wang Xin , Chen Xiang , Zuo Yan-Qin , Liu Ting-Ting , Zheng Jia-Ling , Yang Xin , Illes Peter , Tang Yong TITLE=Association of the ADORA2A receptor and CD73 polymorphisms with epilepsy JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1152667 DOI=10.3389/fphar.2023.1152667 ISSN=1663-9812 ABSTRACT=
Single-nucleotide polymorphisms are connected with the risk of epilepsy on occurrence, progress, and the individual response to drugs. Progress in genomic technology is exposing the complex genetic architecture of epilepsy. Compelling evidence has demonstrated that purines and adenosine are key mediators in the epileptic process. Our previous study found the interconnection of P2Y12 receptor single-nucleotide polymorphisms and epilepsy. However, little is known about the interaction between the purine nucleoside A2A receptor and rate-limiting enzyme ecto-5′-nucleotidase/CD73 and epilepsy from the genetic polymorphism aspect. The aim of the study is to evaluate the impact of A2AR and CD73 polymorphisms on epilepsy cases. The study group encompassed 181 patients with epilepsy and 55 healthy volunteers. A significant correlation was confirmed between CD73 rs4431401 and epilepsy (